SI9111227B - Farmacevtski preprat z aktivno materijo Flupirtin za zdravljenje bolezni, ki se nanašajo na napetost mišic - Google Patents

Farmacevtski preprat z aktivno materijo Flupirtin za zdravljenje bolezni, ki se nanašajo na napetost mišic Download PDF

Info

Publication number
SI9111227B
SI9111227B SI9111227A SI9111227A SI9111227B SI 9111227 B SI9111227 B SI 9111227B SI 9111227 A SI9111227 A SI 9111227A SI 9111227 A SI9111227 A SI 9111227A SI 9111227 B SI9111227 B SI 9111227B
Authority
SI
Slovenia
Prior art keywords
flupirtine
pharmaceutical composition
muscle tension
active agent
disease
Prior art date
Application number
SI9111227A
Other languages
English (en)
Slovenian (sl)
Other versions
SI9111227A (en
Inventor
Michael Lobisch
Ralph Venhaus
Bernd Nickel
Istvan Szelenyi
Juergen Engel
Peter Emig
Original Assignee
Asta Medica Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Aktiengesellschaft filed Critical Asta Medica Aktiengesellschaft
Priority claimed from YU122791A external-priority patent/YU48054B/sh
Publication of SI9111227A publication Critical patent/SI9111227A/sl
Publication of SI9111227B publication Critical patent/SI9111227B/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Golf Clubs (AREA)
  • Details Of Television Scanning (AREA)
  • Paints Or Removers (AREA)
SI9111227A 1990-07-14 1991-07-12 Farmacevtski preprat z aktivno materijo Flupirtin za zdravljenje bolezni, ki se nanašajo na napetost mišic SI9111227B (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
IN421CA1991 IN172468B (cg-RX-API-DMAC7.html) 1990-07-14 1991-06-04
YU122791A YU48054B (sh) 1990-07-14 1991-07-12 Postupak za proizvodnju farmaceutskog preparata

Publications (2)

Publication Number Publication Date
SI9111227A SI9111227A (en) 1995-06-30
SI9111227B true SI9111227B (sl) 2000-12-31

Family

ID=25895002

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9111227A SI9111227B (sl) 1990-07-14 1991-07-12 Farmacevtski preprat z aktivno materijo Flupirtin za zdravljenje bolezni, ki se nanašajo na napetost mišic

Country Status (30)

Country Link
US (2) US5162346A (cg-RX-API-DMAC7.html)
EP (2) EP0467164B1 (cg-RX-API-DMAC7.html)
KR (1) KR0182811B1 (cg-RX-API-DMAC7.html)
CN (1) CN1070700C (cg-RX-API-DMAC7.html)
AT (2) ATE206919T1 (cg-RX-API-DMAC7.html)
AU (1) AU634073B2 (cg-RX-API-DMAC7.html)
CA (1) CA2046943C (cg-RX-API-DMAC7.html)
CZ (1) CZ280879B6 (cg-RX-API-DMAC7.html)
DE (3) DE59107331D1 (cg-RX-API-DMAC7.html)
DK (2) DK0659410T3 (cg-RX-API-DMAC7.html)
EG (1) EG19814A (cg-RX-API-DMAC7.html)
ES (2) ES2164111T3 (cg-RX-API-DMAC7.html)
GR (1) GR3019179T3 (cg-RX-API-DMAC7.html)
HR (1) HRP920667B1 (cg-RX-API-DMAC7.html)
HU (1) HU206973B (cg-RX-API-DMAC7.html)
IE (1) IE74688B1 (cg-RX-API-DMAC7.html)
IL (1) IL98810A (cg-RX-API-DMAC7.html)
IN (1) IN172468B (cg-RX-API-DMAC7.html)
LT (1) LT3593B (cg-RX-API-DMAC7.html)
LV (1) LV10048B (cg-RX-API-DMAC7.html)
MC (1) MC2272A1 (cg-RX-API-DMAC7.html)
MX (1) MX9100160A (cg-RX-API-DMAC7.html)
NO (1) NO912758L (cg-RX-API-DMAC7.html)
NZ (1) NZ238940A (cg-RX-API-DMAC7.html)
PT (1) PT98291B (cg-RX-API-DMAC7.html)
RO (1) RO108220B1 (cg-RX-API-DMAC7.html)
RU (1) RU2070408C1 (cg-RX-API-DMAC7.html)
SI (1) SI9111227B (cg-RX-API-DMAC7.html)
SK (1) SK279567B6 (cg-RX-API-DMAC7.html)
ZA (1) ZA915466B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59307753D1 (de) * 1992-03-11 1998-01-15 Asta Medica Ag Tabletten, Granulate und Pellets mit hohem Gehalt an Wirkstoffen für hochkonzentrierte, feste Darreichungsformen
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
JP2003530308A (ja) * 1999-08-03 2003-10-14 アーヴェーデー.ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 犬および猫の退行性関節疾患に起因する痛みを軽減するためのフルピルチンの使用
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
KR20060124731A (ko) * 2004-01-29 2006-12-05 뉴로몰레큘라 파마슈티칼스, 인코포레이티드 중추신경계-관련 질환 치료용 nmda 수용체 길항제 및mao-억제제 또는 gadph-억제제의 배합물
US20050220862A1 (en) 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
PL1874282T3 (pl) 2005-04-06 2011-04-29 Adamas Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń OUN
CA2650853A1 (en) * 2006-05-02 2007-11-15 Chris Rundfeldt Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
PL2061465T3 (pl) * 2006-08-23 2014-03-31 Valeant Pharmaceuticals Int Pochodne 4-(N-azacykloalkilo) anilidów jako modulatory kanałów potasowych
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
ATE538084T1 (de) * 2006-11-28 2012-01-15 Valeant Pharmaceuticals Int Bicyclische 1,4-retigabin-analoga als kaliumkanalhemmer
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
CA2694887A1 (en) * 2007-08-01 2009-02-05 Henriette Husum Bak-Jensen Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CN114667146A (zh) 2019-11-08 2022-06-24 泽农医药公司 治疗抑郁症的方法
MX2023009314A (es) 2021-02-09 2023-08-16 Xenon Pharmaceuticals Inc Apertura del canal de potasio dependiente de voltaje para usarse en el tratamiento de la anhedonia.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
ATE46265T1 (de) * 1985-01-23 1989-09-15 Asta Pharma Ag Synergistische kombination von flupirtin und nicht-steroidalen antiphlogistika.
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
ATE43789T1 (de) * 1985-02-23 1989-06-15 Asta Pharma Ag Kombination von flupirtin und anticholinergisch wirkenden spasmolytika.
FI855016L (fi) * 1985-06-28 1986-12-29 Degussa Synergistisk kombination av flupirtin och 4-acetamido-fenol.

Also Published As

Publication number Publication date
IL98810A0 (en) 1992-07-15
GR3019179T3 (en) 1996-06-30
LV10048A (lv) 1994-05-10
RO108220B1 (ro) 1994-03-31
DE4122166A1 (de) 1992-01-16
US5284861A (en) 1994-02-08
KR0182811B1 (ko) 1999-05-01
AU8040391A (en) 1992-01-16
AU634073B2 (en) 1993-02-11
HU206973B (en) 1993-03-01
MC2272A1 (fr) 1993-06-23
PT98291A (pt) 1992-05-29
MX9100160A (es) 1992-02-28
NO912758D0 (no) 1991-07-12
IL98810A (en) 1996-01-19
EP0467164B1 (de) 1996-01-31
LV10048B (en) 1995-06-20
ES2082887T3 (es) 1996-04-01
EP0659410A2 (de) 1995-06-28
SK279567B6 (sk) 1999-01-11
EP0467164A3 (en) 1992-04-15
ATE133564T1 (de) 1996-02-15
DE59109222D1 (de) 2001-11-22
KR920002147A (ko) 1992-02-28
LT3593B (en) 1995-12-27
CZ280879B6 (cs) 1996-04-17
IE912451A1 (en) 1992-01-15
ZA915466B (en) 1992-04-29
HUT59313A (en) 1992-05-28
CN1058716A (zh) 1992-02-19
IE74688B1 (en) 1997-07-30
ATE206919T1 (de) 2001-11-15
PT98291B (pt) 1999-01-29
NZ238940A (en) 1997-05-26
EP0659410B1 (de) 2001-10-17
EP0659410A3 (de) 1995-10-25
CA2046943A1 (en) 1992-01-15
US5162346A (en) 1992-11-10
CS210191A3 (en) 1992-02-19
IN172468B (cg-RX-API-DMAC7.html) 1993-08-14
DE59107331D1 (de) 1996-03-14
CA2046943C (en) 1996-03-12
NO912758L (no) 1992-01-15
SI9111227A (en) 1995-06-30
HRP920667A2 (en) 1996-10-31
ES2164111T3 (es) 2002-02-16
DK0467164T3 (da) 1996-03-04
DK0659410T3 (da) 2001-12-27
EP0467164A2 (de) 1992-01-22
HU912359D0 (en) 1991-12-30
LTIP919A (en) 1995-03-27
CN1070700C (zh) 2001-09-12
RU2070408C1 (ru) 1996-12-20
HRP920667B1 (en) 1998-06-30
EG19814A (en) 1996-02-29

Similar Documents

Publication Publication Date Title
SI9111227B (sl) Farmacevtski preprat z aktivno materijo Flupirtin za zdravljenje bolezni, ki se nanašajo na napetost mišic
BR0010498A (pt) Composições modernas de medicamentos à base de compostos anticolinergicamente ativos e beta-miméticos
BR0315283A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de doenças neurológicas ou de doenças inflamatórias do trato respiratório superior
BR0014525A (pt) Processo de tratamento de distúrbios metabólicos, especialmente diabetes, ou uma doença ou condição associada com diabetes
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
KR900700089A (ko) 전신성 피부 투과적 투여를 위한 약학적 조성물
BR0312216A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito que sofre de uma doença ou condição patológica e combinação de produto
SE7910501L (sv) Lekemedel for behandling av det centrala nervsystemet
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR0311558A (pt) composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, métodos para afetar os receptores de glutamato metabotrópicos ligados a camp, para administrar uma quantidade eficaz de um composto e para tratar um distúrbio neurológico e psiquiátrico em um paciente, e, formulação farmacêutica
MX9204881A (es) Composicion farmaceutica que comprende moleculas activas, receptoras de calcio.
FI935847A0 (fi) L-DOPA-esterkompositioner
BE882833A (fr) Sels mixtes d'acides amines essentiels ou semi-essentiels et de leurs analogues exempts d'azote, en utilisant pour traiter des desordres renaux
PT920865E (pt) Utilizacao de ""norastemizole"" para o tratamento de disturbios alergicos
DK0501705T3 (da) Anvendelse af tomoxetin til behandling af sygdomme i de nedre urinveje
ES8400742A1 (es) Procedimiento de preparacion de las dibenzooxepinas sustituidas y de sus sales de adicion con un acido mineral u organi-co.
DE10299023I1 (de) Antineoplastisch wirkender und den Antineoplastischen effekt Verstaerkender Wirkstoff
IL90418A0 (en) Condensed diazepinones,their preparation and pharmaceutical compositions containing them
DK121789D0 (da) 4,5,6,7-tetrahydroisothiazole oe4,5-caapyridinderivater
BR9813020A (pt) Utilização de derivados de ácido lisofosfatidìlico, compostos e drogas que contém esses compostos
DE3275060D1 (en) Use of beta-(1-adamantyl)-alpha, alpha-dimethylethylamine for the manufacture of a medicament for the treatment of otitis externa in dogs
EP0297630A1 (de) Arzneimittel, enthaltend Lokalanästhetika und Nukleoside
GR3019176T3 (en) Medicament containing a combination of AZT and amantadin for the treatment of AIDS.
US3686409A (en) Combination of l-dopa and 2-imino-5-phenyl-4-oxazolidinone used to treat parkinson{40 s disease
KR910018026A (ko) α-페닐-α피리딜알칸산 유도체를 함유하는 배뇨장애증상 치료제

Legal Events

Date Code Title Description
IF Valid on the event date